A germline mutation in the BRCA1 3'UTR predicts Stage IV breast cancer

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Dorairaj, Jemima J ^a   Salzman, David W ^b   Wall, Deirdre ^a   Rounds, Tiffany ^c   Preskill, Carina ^b   Sullivan, Catherine A W ^b   Lindner, Robert ^d   Curran, Catherine ^a   Lezon Geyda, Kim ^b   McVeigh, Terri ^a   Harris, Lyndsay ^b   Newell, John ^a   Kerin, Michael J ^a   Wood, Marie ^c   Miller, Nicola ^a   Weidhaas, Joanne B ^b  

^a NATIONAL UNIVERSITY OF IRELAND   (Ireland)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biomarker; BRCA1 3'UTR variant; Breast cancer; Diagnostic marker; Metastatic breast cancer; Mutation; Stage IV breast cancer

Indexed keywords

LUCIFERASE; 3' UNTRANSLATED REGION; BRCA1 PROTEIN;

3' UNTRANSLATED REGION; ARTICLE; CANCER CELL LINE; CANCER RISK; CANCER STAGING; CANCER TISSUE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GERMLINE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IN VITRO STUDY; IN VIVO STUDY; OBESITY; PHENOTYPE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; DISEASE FREE SURVIVAL; GENE EXPRESSION REGULATION; GENETICS; PATHOLOGY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL;

3' UNTRANSLATED REGIONS; BRCA1 PROTEIN; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84902546055     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-421     Document Type: Article

References (42)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55(2):74-108. 10.3322/canjclin.55.2.74, 15761078.
2. Parkin DM, Fernandez LM. Use of statistics to assess the global burden of breast cancer. Breast J 2006, 12(Suppl 1):S70-S80.
3. Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, Muller SH, Meijer S, Oosterwijk JC, Beex LV, Tollenaar RA, de Koning HJ, Rutgers EJ, Klijn JG. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. N Engl J Med 2004, 351(5):427-437. 10.1056/NEJMoa031759, 15282350.
4. El Saghir NS, Seoud M, Khalil MK, Charafeddine M, Salem ZK, Geara FB, Shamseddine AI. Effects of young age at presentation on survival in breast cancer. BMC Cancer 2006, 6:194. 10.1186/1471-2407-6-194, 1555600, 16857060.
5. Remak E, Brazil L. Cost of managing women presenting with stage IV breast cancer in the United Kingdom. Br J Cancer 2004, 91(1):77-83. 10.1038/sj.bjc.6601890, 2364734, 15188011.
6. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 2000, 342(8):525-533. 10.1056/NEJM200002243420801, 10684910.
7. Gayther SA, Warren W, Mazoyer S, Russell PA, Harrington PA, Chiano M, Seal S, Hamoudi R, van Rensburg EJ, Dunning AM, Love R, Evans G, Easton D, Clayton D, Stratton MR, Ponder BA. Germline variants of the BRCA1 gene in breast and ovarian cancer families provide evidence for a genotype-phenotype correlation. Nat Genet 1995, 11(4):428-433. 10.1038/ng1295-428, 7493024.
8. Hall JM, Lee MK, Newman B, Morrow JE, Anderson LA, Huey B, King MC. Linkage of early-onset familial breast cancer to chromosome 17q21. Science 1990, 250(4988):1684-1689. 10.1126/science.2270482, 2270482.
9. Huen MS, Sy SM, Chen J. BRCA1 and its toolbox for the maintenance of genome integrity. Nat Rev Mol Cell Biol 2010, 11(2):138-148. 10.1038/nrm2831, 3899800, 20029420.
10. Venkitaraman AR. Functions of BRCA1 and BRCA2 in the biological response to DNA damage. J Cell Sci 2001, 114(Pt 20):3591-3598.
11. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol 2007, 25(11):1329-1333. 10.1200/JCO.2006.09.1066, 2267287, 17416853.
12. Easton DF, Ford D, Bishop DT. Breast and ovarian cancer incidence in BRCA1-variant carriers. Breast Cancer Linkage Consortium. Am J Hum Genet 1995, 56(1):265-271. 1801337, 7825587.
13. Ford D, Easton DF, Bishop DT, Narod SA, Goldgar DE. Risks of cancer in BRCA1-variant carriers. Breast Cancer Linkage Consortium. Lancet 1994, 343(8899):692-695. 10.1016/S0140-6736(94)91578-4, 7907678.
14. Ford D, Easton DF, Stratton M, Narod S, Goldgar D, Devilee P, Bishop DT, Weber B, Lenoir G, Chang-Claude J, Sobol H, Teare MD, Struewing J, Arason A, Scherneck S, Peto J, Rebbeck TR, Tonin P, Neuhausen S, Barkardottir R, Eyfjord J, Lynch H, Ponder BA, Gayther SA, Zelada-Hedman M. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium. Am J Hum Genet 1998, 62(3):676-689. 10.1086/301749, 1376944, 9497246.
15. King MC, Marks JH, Mandell JB. Breast and ovarian cancer risks due to inherited variants in BRCA1 and BRCA2. Science 2003, 302(5645):643-646. 10.1126/science.1088759, 14576434.
16. Pongsavee M, Yamkamon V, Dakeng S. P Oc, Smith DR, Saunders GF, Patmasiriwat P: the BRCA1 3'-UTR: 5711 + 421 T/T_5711 + 1286 T/T genotype is a possible breast and ovarian cancer risk factor. Genet Test Mol Biomarkers 2009, 13(3):307-317. 10.1089/gtmb.2008.0127, 19405875.
17. Pelletier C, Speed WC, Paranjape T, Keane K, Blitzblau R, Hollestelle A, Safavi K, van den Ouweland A, Zelterman D, Slack FJ, Kidd KK, Weidhaas JB. Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle 2011, 10(1):90-99. 10.4161/cc.10.1.14359, 3048078, 21191178.
18. Foulkes WD, Stefansson IM, Chappuis PO, Begin LR, Goffin JR, Wong N, Trudel M, Akslen LA. Germline BRCA1 variants and a basal epithelial phenotype in breast cancer. J Natl Cancer Inst 2003, 95(19):1482-1485. 10.1093/jnci/djg050, 14519755.
19. Olopade OI, Grushko T. Gene-expression profiles in hereditary breast cancer. N Engl J Med 2001, 344(26):2028-2029.
20. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, Deng S, Johnsen H, Pesich R, Geisler S, Demeter J, Perou CM, Lonning PE, Brown PO, Borresen-Dale AL, Botstein D. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003, 100(14):8418-8423. 10.1073/pnas.0932692100, 166244, 12829800.
21. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swaisland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA variant carriers. N Engl J Med 2009, 361(2):123-134. 10.1056/NEJMoa0900212, 19553641.
22. Salzman DW, Weidhaas JB. SNPing cancer in the bud: MicroRNA and microRNA-target site polymorphisms as diagnostic and prognostic biomarkers in cancer. Pharmacol Ther 2013, 137(1):55-63. 10.1016/j.pharmthera.2012.08.016, 3546232, 22964086.
23. Babar IA, Slack FJ. Weidhaas JB: miRNA modulation of the cellular stress response. Future Oncol 2008, 4(2):289-298. 10.2217/14796694.4.2.289, 18407740.
24. Castellano L, Giamas G, Jacob J, Coombes RC, Lucchesi W, Thiruchelvam P, Barton G, Jiao LR, Wait R, Waxman J, Hannon GJ, Stebbing J. The estrogen receptor-alpha-induced microRNA signature regulates itself and its transcriptional response. Proc Natl Acad Sci U S A 2009, 106(37):15732-15737. 10.1073/pnas.0906947106, 2747188, 19706389.
25. Wilson CA, Ramos L, Villasenor MR, Anders KH, Press MF, Clarke K, Karlan B, Chen JJ, Scully R, Livingston D, Zuch RH, Kanter MH, Cohen S, Calzone FJ, Slamon DJ. Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas. Nat Genet 1999, 21(2):236-240. 10.1038/6029, 9988281.
26. Perez-Valles A, Martorell-Cebollada M, Nogueira-Vazquez E, Garcia-Garcia JA, Fuster-Diana E. The usefulness of antibodies to the BRCA1 protein in detecting the mutated BRCA1 gene. An immunohistochemical study. J Clin Pathol 2001, 54(6):476-480. 10.1136/jcp.54.6.476, 1731451, 11376024.
27. Alamshah A, Springall R, Gillett CE, Solomon E, Morris JR. Use of a BRCA1 peptide validates MS110 as a BRCA1-specific antibody in immunohistochemistry. Histopathology 2008, 53(1):117-120. 10.1111/j.1365-2559.2008.03049.x, 18462360.
28. Camp RL, Chung GG, Rimm DL. Automated subcellular localization and quantification of protein expression in tissue microarrays. Nat Med 2002, 8(11):1323-1327. 10.1038/nm791, 12389040.
29. McCabe A, Dolled-Filhart M, Camp RL, Rimm DL. Automated quantitative analysis (AQUA) of in situ protein expression, antibody concentration, and prognosis. J Natl Cancer Inst 2005, 97(24):1808-1815. 10.1093/jnci/dji427, 16368942.
30. Rio DC, Ares M, Hannon GJ, Nilsen TW. Purification of RNA using TRIzol (TRI reagent). Cold Spring Harb Protoc 2010, 6:pdb prot5439.
31. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408. 10.1006/meth.2001.1262, 11846609.
32. Paranjape T, Heneghan H, Lindner R, Keane FK, Hoffman A, Hollestelle A, Dorairaj J, Geyda K, Pelletier C, Nallur S, Martens JW, Hooning MJ, Kerin M, Zelterman D, Zhu Y, Tuck D, Harris L, Miller N, Slack F, Weidhaas J. A 3'-untranslated region KRAS variant and triple-negative breast cancer: a case-control and genetic analysis. Lancet Oncol 2011, 12(4):377-386. 10.1016/S1470-2045(11)70044-4, 3488438, 21435948.
33. Ghosh MG, Thompson DA, Weigel RJ. PDZK1 and GREB1 are estrogen-regulated genes expressed in hormone-responsive breast cancer. Cancer Res 2000, 60(22):6367-6375.
34. Roberts M, Wallace J, Jeltsch JM, Berry M. The 5' flanking region of the human pS2 gene mediates its transcriptional activation by estrogen in MCF-7 cells. Biochem Biophys Res Commun 1988, 151(1):306-313. 10.1016/0006-291X(88)90594-3, 2450536.
35. Day N, Warren R. Mammographic screening and mammographic patterns. Breast Cancer Res 2000, 2(4):247-251. 10.1186/bcr64, 138783, 11250716.
36. Mandelson MT, Oestreicher N, Porter PL, White D, Finder CA, Taplin SH, White E. Breast density as a predictor of mammographic detection: comparison of interval- and screen-detected cancers. J Natl Cancer Inst 2000, 92(13):1081-1087. 10.1093/jnci/92.13.1081, 10880551.
37. Nothacker M, Duda V, Hahn M, Warm M, Degenhardt F, Madjar H, Weinbrenner S, Albert US. Early detection of breast cancer: benefits and risks of supplemental breast ultrasound in asymptomatic women with mammographically dense breast tissue. A systematic review. BMC Cancer 2009, 9:335. 10.1186/1471-2407-9-335, 2760575, 19765317.
38. Thompson ME, Jensen RA, Obermiller PS, Page DL, Holt JT. Decreased expression of BRCA1 accelerates growth and is often present during sporadic breast cancer progression. Nat Genet 1995, 9(4):444-450. 10.1038/ng0495-444, 7795653.
39. Larson JS, Tonkinson JL, Lai MT. A BRCA1 mutant alters G2-M cell cycle control in human mammary epithelial cells. Cancer Res 1997, 57(16):3351-3355.
40. Lee WY, Jin YT, Chang TW, Lin PW, Su IJ. Immunolocalization of BRCA1 protein in normal breast tissue and sporadic invasive ductal carcinomas: a correlation with other biological parameters. Histopathology 1999, 34(2):106-112. 10.1046/j.1365-2559.1999.00578.x, 10064388.
41. Seery LT, Knowlden JM, Gee JM, Robertson JF, Kenny FS, Ellis IO, Nicholson RI. BRCA1 expression levels predict distant metastasis of sporadic breast cancers. Int J Cancer 1999, 84(3):258-262. 10.1002/(SICI)1097-0215(19990621)84:3<258::AID-IJC10>3.0.CO;2-H, 10371343.
42. Yang Q, Sakurai T, Mori I, Yoshimura G, Nakamura M, Nakamura Y, Suzuma T, Tamaki T, Umemura T, Kakudo K. Prognostic significance of BRCA1 expression in Japanese sporadic breast carcinomas. Cancer 2001, 92(1):54-60. 10.1002/1097-0142(20010701)92:1<54::AID-CNCR1291>3.0.CO;2-8, 11443609.